<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02192853</url>
  </required_header>
  <id_info>
    <org_study_id>H-2-2012-149</org_study_id>
    <nct_id>NCT02192853</nct_id>
  </id_info>
  <brief_title>Correlation Between Plasma- and Endothelial DPP-4 Activity</brief_title>
  <official_title>Plasma and Endothelial Activity of Dipeptidyl Peptidase 4 During Different Doses of Sitagliptin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators want to estimate both the endothelial and the plasma activity of dipeptidyl
      peptidase 4 during different doses of sitagliptin in healthy subjects and patients with type
      2 diabetes. Furthermore, the investigators want to investigate whether the current clinical
      dose of 100 mg of sitagliptin is sufficient to inhibit both the plasma and the endothelial
      activity of the enzyme dipeptidyl peptidase 4.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The two incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent
      insulinotropic polypeptide (GIP) are secreted from the intestinal L- and K- cells,
      respectively in response to ingestion of nutrients. The two hormones are able to lower blood
      glucose levels during high glucose levels - by the so called incretin effect. GIP and GLP-1
      are both rapidly inactivated by the enzyme dipeptidyl peptidase 4 (DPP-4). The remaining
      metabolites are without insulinotropic effects. The effect of DPP-4 inhibitors used in
      treatment of type 2 diabetes relies on their impact on DPP-4 activity.

      DPP-4 exists in a soluble form in plasma ad as a membrane-bound form in blood vessels and
      other tissues. The impact of DPP-4 inhibitors on DPP-4 activity has only been evaluated in
      plasma. We aim to investigate plasma and endothelial DPP-4 activity (i.e. whole-body DPP-4
      activity) in patients with type 2 diabetes during different doses of the DPP-4 inhibitor
      sitagliptin.

      Both healthy control subjects and patients with type 2 diabetes are subjected to 4
      experimental days (in a randomized order) with continuous infusion of GLP-1 and pre-treatment
      with 25 mg sitagliptin, 100 mg sitagliptin, 200 mg sitagliptin and placebo, respectively.
      Afterwards, we are going to measure the whole-body DPP-4 activity by comparing plasma levels
      of active (intact) GLP-1 and total GLP-1, and relate to plasma DPP-4 activity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>intervention was blinded for the participant and the investigator</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between the total and intact GLP-1 hormone during different doses of sitagliptin measured as total area under the curve (tAUC)</measure>
    <time_frame>GLP.1 total and GLP-1 intact will be calculated based on blood samples at time points: -40,-30,-20,-10,0,10,20,30,40,50,60,75,90,105,120,150,180,240,300,360 on all days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences in serum-/plasma concentrations of GLP-1 measured as total Area under the curve (tAUC)</measure>
    <time_frame>GLP-1 will be measured at time points(minutes): -40,-30,-20,-10,0,10,20,30,40,50,60,75,90,105,120,150,180,240,300,360 on all days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in glucose measured as total Area under the curve (tAUC)</measure>
    <time_frame>Glucose will be measured at time points(minutes): -40,-30,-20,-10,0,10,20,30,40,50,60,75,90,105,120,150,180,240,300,360 on all days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in Insulin measured as total Area under the curve (tAUC)</measure>
    <time_frame>Insulin will be measured at time points(minutes): -40,-30,-20,-10,0,10,20,30,40,50,60,75,90,105,120,150,180,240,300,360 on all days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with Type 2 Diabetes Mellitus and healthy control subjects are given tablets of sitagliptin in either a dosage of 25, 100 or 200 mg tablet in 3 different days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sitagliptin</intervention_name>
    <description>In randomized order:
Day 1: tablet of 25 mg of sitagliptin + i.v. GLP-1 infusion Day 2: tablet of 100 mg of sitagliptin + i.v. GLP-1 infusion Day 3: tablet of 200 mg of sitagliptin + i.v. GLP-1 infusion</description>
    <arm_group_label>Sitagliptin</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Day 4: placebo tablet</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Caucasians with diet and/or metformin treated patients with type 2 diabetes (diagnosed
             according to the criterias of the World Health Organization)

          -  Normal Hemoglobin

          -  Prior Informed Consent

        Exclusion Criteria:

          -  Nephropathy

          -  Liver disease

          -  Inflammatory bowel disease

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Filip K Knop, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Gentofte Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tina Vilsbøll, MD DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Gentofte Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Asger Lund, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Gentofte Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Camilla Andersen, Med.stud.</last_name>
    <role>Study Chair</role>
    <affiliation>Gentofte Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jens Juul Holst, MD DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Institute of biomedical sciences, University of Copenhagen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emilie Skytte Andersen, Med.stud.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gentofte Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diabetes Research Division, Department of Endocrinology, Gentofte Hospital</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Deacon CF, Hughes TE, Holst JJ. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes. 1998 May;47(5):764-9.</citation>
    <PMID>9588448</PMID>
  </reference>
  <reference>
    <citation>Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007 Oct;87(4):1409-39. Review.</citation>
    <PMID>17928588</PMID>
  </reference>
  <reference>
    <citation>Holst JJ, Vilsbøll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol. 2009 Jan 15;297(1-2):127-36. doi: 10.1016/j.mce.2008.08.012. Epub 2008 Aug 20. Review.</citation>
    <PMID>18786605</PMID>
  </reference>
  <reference>
    <citation>Orskov C, Wettergren A, Holst JJ. Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes. 1993 May;42(5):658-61.</citation>
    <PMID>8482423</PMID>
  </reference>
  <reference>
    <citation>Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R, Hüfner M, Schmiegel WH. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002 Mar;87(3):1239-46.</citation>
    <PMID>11889194</PMID>
  </reference>
  <reference>
    <citation>Gutzwiller JP, Drewe J, Göke B, Schmidt H, Rohrer B, Lareida J, Beglinger C. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol. 1999 May;276(5 Pt 2):R1541-4.</citation>
    <PMID>10233049</PMID>
  </reference>
  <reference>
    <citation>Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept. 2003 Jul 15;114(2-3):115-21.</citation>
    <PMID>12832099</PMID>
  </reference>
  <reference>
    <citation>Deacon CF. Circulation and degradation of GIP and GLP-1. Horm Metab Res. 2004 Nov-Dec;36(11-12):761-5. Review.</citation>
    <PMID>15655705</PMID>
  </reference>
  <reference>
    <citation>Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, Snyder K, Hilliard D, Tanen M, Tanaka W, Wang AQ, Zeng W, Musson D, Winchell G, Davies MJ, Ramael S, Gottesdiener KM, Wagner JA. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther. 2005 Dec;78(6):675-88.</citation>
    <PMID>16338283</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2014</study_first_submitted>
  <study_first_submitted_qc>July 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2014</study_first_posted>
  <last_update_submitted>September 7, 2017</last_update_submitted>
  <last_update_submitted_qc>September 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Emilie Skytte Andersen</investigator_full_name>
    <investigator_title>Research student</investigator_title>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Glucagon-like peptide 1</keyword>
  <keyword>Dipeptidyl peptidase 4</keyword>
  <keyword>Dipeptidyl peptidase 4 inhibitor</keyword>
  <keyword>sitagliptin</keyword>
  <keyword>Enzyme activity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

